New insights in prediction of ovarian hyperstimulation syndrome

Acta Clinica Croatica

Volumn 50, Issue 2, 2011, Pages 281-288

  Kasum, Miro ^a   Orešković, Slavko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Ovarian hyperstimulation syndrome; Ovulation induction side effects; Predictive value of tests; Risk factors

Indexed keywords

CADHERIN; CHORIONIC GONADOTROPIN; ESTRADIOL; INHIBIN A; INHIBIN B; MUELLERIAN INHIBITING FACTOR; THYROTROPIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AGE; ALLERGY; BLOOD VESSEL PERMEABILITY; BODY MASS; CRYOPRESERVATION; FERTILIZATION IN VITRO; GENE MUTATION; HUMAN; INCIDENCE; MEDICAL HISTORY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELIABILITY; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEROIDOGENESIS; FEMALE; METHODOLOGY;

FEMALE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; RISK FACTORS;

EID: 84856615252     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Whelan J, Vlahos N. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-96.
2. Ludwig M, Gembruch U, Bauer O, Diedrich K. Ovarian hyperstimulation syndrome (OHSS ) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS Hum Reprod 1998;13:2082-7.
3. Semba S, Moriya T, Youseff M, Sasano H. An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. Pathol Int 2000;50:549-52.
4. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS ). Hum Reprod Update 2003;fali volumen:77-96.
5. Al-Shawaf T, Grundzikas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynecol Reprod 2003;17:249-61.
6. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321-33.
7. Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J. Implantation is apparently unaffected by dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-4.
8. Villasante A, Pacheco A, Pau E, Ruiz A, Pellicer A, Garcia-Velasco JA. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 2008;23:662-7.
9. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-89.
10. Garcia-Velasco JA, Isaza V, Quea G. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing ? Fertil Steril 2006;85:547-54.
11. Vrtovec HM , Tomaževič T. Preventing severe ovarian hyperstimulation syndrome in in vitro fertilization/ embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration. J Reprod Med 1995;40:37-40.
12. Egbase P, Sharfan MA, Grudzinkas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 1999;14:1421-5.
13. Chen SU , Chen CD, Yang YS. Ovarian stimulation syndrome (OHSS ): new strategies of prevention and treatment. J Formos Med Assoc 2008;17:509-12.
14. Smith LP , Hacker MR, Alper MM. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril 2009;92;1953-9.
15. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS ): a review. Hum Reprod Update 2002;8:559-77.
16. E l-Sheikh MM, Husein M, Fuad S, El-Sheikh R, Bauer O, Al-Hasani R. Limited ovarian stimulation (LOS ) prevents the recurrence of severe forms of hyperstimulation syndrome in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1996;94:245-9.
17. Aboulghar A, Mansour RT, Serour GI , Rhodes CA, Amin YM. Reduction of human gonadotropin dose followed by coasting of severe ovarian hyperstimulation syndrome. J Assist Reprod Genet 2000;417:298-301.
18. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808-14.
19. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Margolioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988;159:210-5.
20. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005;84:611-6.
21. Lass A, Vassiliev A, Decosterd G, Warne D, Loumaye E. Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropin. Fertil Steril 2002;78:265-9.
22. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, et al. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000;73:972-7.
23. Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A, et al. The impact of insulin on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:644-6.
24. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, et al. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic disease. Hum Reprod 1998;13:651-5.
25. Ficicioglu C, Kutlu C, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592-6.
26. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian reserve in assisted reproductive technology. Hum Reprod 2007;22:766-71.
27. Cook L, Siow Y, Brenner AG, Fallat ME. Realationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77:141-6.
28. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-mullerian hormone. Reproduction 2002;124:601-9.
29. Nakhuda GS , Chu MC, Wang JG, Sauer MV , Lobo RA. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006;85:1541-3.
30. Lee TH , Liu CH, Huang CC, Wu LL , Shih YT , Ho HN, et al. Serum anti-mullerian hormone and estradiol as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology. Hum Reprod 2008;23:160-7.
31. Homburg R, Insler V. Ovulation induction in perspective. Hum Reprod Update 2002;8:449-62.
32. Hughes RA, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000 (2) CD000087.
33. Humaidan P, Papanikolaou EG , Tarlatzis BC. GnRha to trigger final oocyte maturation: a time to consider. Hum Reprod 2009;24:2389-94.
34. Aboulghar M. Luteal support in reproduction: when, what, and how ? Curr Opin Obstet Gynecol 2009;21:279-84.
35. Shimon I, Rubinek T, Bar-Hava I, Nass D, Hadani M, Amsterdam A, et al. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone secreting pituitary adenoma. J Clin Endocrinol Metab 2001;86:3635-40.
36. Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS ). Hum Reprod 2003;18:1140-1.
37. Papan ikolaou NG, Pozzobon C, Kolibiana-kis EM , Camus M, Tournaye H, Faterni HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112-20.
38. Aramwit P, Pruksananonda K, Kasettra-tat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 2008;65:1148-53.
39. Favzy M, Lambert A, Harrison RF, Knight PG , Groome N, Hennelly B. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod 2002;17:1535-43.
40. Moos J, Rezabek K, Filova V, Moosova M, Pavelkova J, Peknicova J. Comparison of follicular fluid and serum levels inhibin A and inhibin B calculated indices used as predictive markers of ovarian hyperstimulation syndrome in IVF patients. Reprod Biol Endocrinol 2009;24:7-12.
41. Daelemans C, Smits G, De Maertelaer V, Costagliola S, Englert Y, Vassar t G, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation by follicle-stimulating hormone receptor Ser680Asn polymorphisms. J Clin Endocrinol Metab 2004;89:6310-5.
42. Rizk B. Symposium: Update on Prediction and Management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biol Online 2009;19:14-27.
43. Lussiana C, Guani B, Mari C, Restagno G, Massobrio M, Revelli A. Mutations and polymorphisms of the FSH receptor (FSH ) gene: clinical implications in female fecundity and molecular biology of FSH protein gene. Obstet Gynecol Surg 2008;63:785-95